Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Cancer Letters|February 21, 2021
Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repairSilvia Codenotti, Francesco Marampon, Luca Triggiani, et al.
Cancers|November 26, 2022
Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical ApplicationsSilvia Sideri, Francesco Petragnano, Roberto Maggio, et al.
Molecular Cancer Therapeutics|January 12, 2011
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signalsFrancesco Marampon, Giovanni Luca Gravina, Agnese Di Rocco, et al.
Radiation Oncology Journal|February 10, 2025
Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment responseFrancesco Marampon, Giovanni Luca Gravina, Elisa Cinelli, et al.
Cancer Letters|March 27, 2017
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cellsFrancesco Marampon, Francesca Megiorni, Simona Camero, et al.
International Journal of Oncology|November 6, 2013
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell linesFrancesco Marampon, Giovanni Luca Gravina, Valdimir M Popov, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysisLetizia Ferella, Erika Limoncin, Francesca Vittorini, et al.
Frontiers in Pharmacology|October 5, 2020
The Botanical Drug PBI-05204, a Supercritical CO<sub>2</sub> Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal PropertiesAlessandro Colapietro, Peiying Yang, Alessandra Rossetti, et al.
Journal of Cancer Research and Clinical Oncology|July 27, 2019
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastomaFrancesco Marampon, Flavio Leoni, Andrea Mancini, et al.
Brain Sciences|July 29, 2025
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and TemozolomidePaolo Tini, Flavio Donnini, Francesco Marampon, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Cancer Letters|February 21, 2021
Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repairSilvia Codenotti, Francesco Marampon, Luca Triggiani, et al.
Cancers|November 26, 2022
Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical ApplicationsSilvia Sideri, Francesco Petragnano, Roberto Maggio, et al.
Molecular Cancer Therapeutics|January 12, 2011
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signalsFrancesco Marampon, Giovanni Luca Gravina, Agnese Di Rocco, et al.
Radiation Oncology Journal|February 10, 2025
Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment responseFrancesco Marampon, Giovanni Luca Gravina, Elisa Cinelli, et al.
Cancer Letters|March 27, 2017
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cellsFrancesco Marampon, Francesca Megiorni, Simona Camero, et al.
International Journal of Oncology|November 6, 2013
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell linesFrancesco Marampon, Giovanni Luca Gravina, Valdimir M Popov, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysisLetizia Ferella, Erika Limoncin, Francesca Vittorini, et al.
Frontiers in Pharmacology|October 5, 2020
The Botanical Drug PBI-05204, a Supercritical CO<sub>2</sub> Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal PropertiesAlessandro Colapietro, Peiying Yang, Alessandra Rossetti, et al.
Journal of Cancer Research and Clinical Oncology|July 27, 2019
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastomaFrancesco Marampon, Flavio Leoni, Andrea Mancini, et al.
Brain Sciences|July 29, 2025
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and TemozolomidePaolo Tini, Flavio Donnini, Francesco Marampon, et al.
Pageof 16